Merger Pending
Passage Bio and Remix Therapeutics merger
Announced 24 Jun 2026
Advisers
Other advisers
- Financial adviser
- Target
- Remix Therapeutics
- Acquirer
- Passage Bio
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development, Oncology
In the league tables
Similar deals
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Rallybio acquisition of Avenzo Therapeutics Jun 2026 · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
Sources
- Jun 2026 Latham Watkins Advises Remix Therapeutics in Merger With Passage Bio lw.com
- 24 Jun 2026 Press release (EX-99.1, exhibit), Passage Bio and Remix Therapeutics Announce sec.gov
